Variables | Pre-treatment NLR | P value | |
<2.57 (n= 316) | ≥2.57 (n = 72) | ||
Age (years) | 47.34 ± 10.03 | 46.85 ± 10.45 | 0.49 |
Menopausal status: · Pre-menopausal · Post-menopausal |
154 (48.8%) 162 (51.2%) |
37 (51.8%) 35 (48.2%) | 0.36 |
Pathological type: · IDC · ILC · Mixed · DCIS · Others |
285 (90.1%) 15 (4.6%) 4 (1.3%) 1 (0.3%) 11(3.6%) |
65 (90.6%) 3 (4.7%) 0 1 (1.2%) 3 (3.5%) | 0.72 |
Histological grade: · Grade I · Grade II · Grade III |
4 (1.3%) 268 (88.4%) 31 (10.2%) |
1 (1.2%) 76 (89.4%) 8 (9.5%) | 0.06 |
Tumor stage: · T1 · T2 · T3 · T4 · Tx |
27 (8.3%) 181 (57.4%) 59 (18.8%) 30 (9.6%) 19 (5.9%) |
6 (8.2%) 35 (49.4%) 14 (18.8%) 12 (17.6%) 5 (5.9%) | 0.33 |
Nodal stage: · N0 · N1 · N2 · N3 · Nx |
95 (30%) 106 (33.7%) 53 (16.8%) 48 (15.2%) 14 (4.3%) |
21 (29.4%) 21 (29.4%) 9 (12.9%) 16 (22.4%) 5 (5.9%) | 0.49 |
Hormone receptor status: · ER/PR positive · ER positive and PR negative · ER negative and PR positive · ER/PR negative |
163 (51.4%) 42 (13.2%) 9 (2.9%) 102 (32.2%) |
38 (52.9%) 7 (10.6%) 2 (2.4%) 25 (34.1%) | 0.09 |
HER-2 neu expression (by IHC): · 0/+1 · +2 · +3 · Unknown |
87 (27.4%) 18 (5.3%) 35 (11.6%) 176 (55.8%) |
22 (30.6%) 4 (4.7%) 2 (3.5%) 44 (61.2%) | 0.17 |
Triple negative: | 22 (7%) | 8 (10.6%) | 0.21 |